<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">pulmo</journal-id><journal-title-group><journal-title xml:lang="ru">Пульмонология</journal-title><trans-title-group xml:lang="en"><trans-title>PULMONOLOGIYA</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0869-0189</issn><issn pub-type="epub">2541-9617</issn><publisher><publisher-name>Scientific and Practical Journal “PULMONOLOGIYA” LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18093/0869-0189-2026-36-2-208-216</article-id><article-id custom-type="elpub" pub-id-type="custom">pulmo-4875</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL STUDIES</subject></subj-group></article-categories><title-group><article-title>Генотипические и фенотипические характеристики взрослых пациентов с муковисцидозом в Республике Казахстан</article-title><trans-title-group xml:lang="en"><trans-title>Genotypic and phenotypic characteristics of adults with cystic fibrosis in the Republic of Kazakhstan</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0008-5057-106X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ким</surname><given-names>С. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kim</surname><given-names>S. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ким Салтанат Сулейменовна — врач-пульмонолог, магистр медицины, кафедра внутренних болезней № 3</p><p>010000, Астана, ул. Бейбитшилик, 49А</p><p> </p></bio><bio xml:lang="en"><p>Saltanat S. Kim, Pulmonologist, Master of Medicine, Department of Internal Medicine No.3</p><p>ul. Beibitshilik 49a, Astana, 010000</p></bio><email xlink:type="simple">kimsaltanat1990@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5804-8643</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мукатова</surname><given-names>И. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Mukatova</surname><given-names>I. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мукатова Ирина Юрьевна — д. м. н., профессор, кафедра внутренних болезней № 3</p><p>010000, Астана, ул. Бейбитшилик, 49А</p><p> </p></bio><bio xml:lang="en"><p>Irina Yu. Mukatova, Doctor of Medicine, Professor, Department of Internal Medicine No.3</p><p>ul. Beibitshilik 49a, Astana, 010000</p><p>Scopus Author ID: 57221914378;</p><p>Web of Science Researcher ID: ABB-8448-2021</p></bio><email xlink:type="simple">irinamukatova24@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-5356-9415</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Амелина</surname><given-names>Е. Л.</given-names></name><name name-style="western" xml:lang="en"><surname>Amelina</surname><given-names>E. L.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Амелина Елена Львовна — к. м. н., ведущий научный сотрудник лабо­ратории муковисцидоза Федерального государственного бюджетного учреждения «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства; аффилированный профессор Некоммерческого акционерного общества «Медицинский университет Астана» Министерства здравоохранения Республики Ка­захстан</p><p>010000, Астана, ул. Бейбитшилик, 49А,</p><p>115682, Москва, Ореховый бульвар, 28</p><p> </p></bio><bio xml:lang="en"><p>Elena L. Amelina, Candidate of Medicine, Leading Researcher, Cystic Fibrosis Laboratory, Federal State Budgetary Institution “Pulmonology Scientific Re­search Institute” under Federal Medical and Biological Agency of Russian Fed­eration; Affiliated Professor, Not Joint Stock Company “Astana Medical Uni­versity”</p><p>ul. Beibitshilik 49a, Astana, 010000,</p><p>Orekhovyy bul’var 28, Moscow, 115682</p><p>Author ID: 7003985681</p></bio><email xlink:type="simple">eamelina@mail.ru</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0009-9314-2473</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Кенжебаева</surname><given-names>Ы. Ж.</given-names></name><name name-style="western" xml:lang="en"><surname>Kenzhebaeva</surname><given-names>Y. Zh.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Кенжебаева Ырысалды Жаксылыковна — врач-пульмонолог, исполня­ющая обязанности заведующей отделением пульмонологии</p><p>010000, Астана, проспект Рахимжана Кошкарбаева, 66</p></bio><bio xml:lang="en"><p>Yryssaldy Zh. Kenzhebayeva, Pulmonologist, Acting Head of the Pulmonology Department</p><p>prosp. Rakhimzhana Koshkarbayeva 66, Astana, 010000</p></bio><email xlink:type="simple">ykenzebaeva@gmal.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3390-700X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Раманкул</surname><given-names>А. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Ramankul</surname><given-names>A. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Раманкул Азиза Садуакасовна — врач-пульмонолог, магистрант 2-го года кафедры внутренних болезней № 3</p><p>010000, Астана, ул. Бейбитшилик, 49А</p></bio><bio xml:lang="en"><p>Aziza S. Ramankul, Pulmonologist, 2nd-year Master’s Student, Department of Internal Medicine No.3</p><p>ul. Beibitshilik 49a, Astana, 010000</p></bio><email xlink:type="simple">aziza93brs93@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Некоммерческое акционерное общество «Медицинский университет Астана» Министерства здравоохранения Республики Казахстан</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>Non-profit Joint Stock Company “Astana Medical University”, Ministry of Health of the Republic of Kazakhstan</institution><country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Некоммерческое акционерное общество «Медицинский университет Астана» Министерства здравоохранения Республики Казахстан;&#13;
Федеральное государственное бюджетное учреждение «Научно-исследовательский институт пульмонологии» Федерального медико-биологического агентства России»</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>Non-profit Joint Stock Company “Astana Medical University”, Ministry of Health of the Republic of Kazakhstan;&#13;
Federal State Budgetary Institution “Pulmonology Scientific Research Institute” under Federal Medical and Biological Agency of Russian Federation</institution><country>Kazakhstan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Государственное коммунальное предприятие на праве хозяйственного ведения «Многопрофильная городская больница № 1» акимата города Астаны</institution><country>Казахстан</country></aff><aff xml:lang="en"><institution>State-Owned Enterprise on Economic Management “Multidisciplinary City Hospital No.1” Akimat of Astana city</institution><country>Kazakhstan</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2026</year></pub-date><pub-date pub-type="epub"><day>17</day><month>04</month><year>2026</year></pub-date><volume>36</volume><issue>2</issue><fpage>208</fpage><lpage>216</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Ким С.С., Мукатова И.Ю., Амелина Е.Л., Кенжебаева Ы.Ж., Раманкул А.С., 2026</copyright-statement><copyright-year>2026</copyright-year><copyright-holder xml:lang="ru">Ким С.С., Мукатова И.Ю., Амелина Е.Л., Кенжебаева Ы.Ж., Раманкул А.С.</copyright-holder><copyright-holder xml:lang="en">Kim S.S., Mukatova I.Y., Amelina E.L., Kenzhebaeva Y.Z., Ramankul A.S.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://journal.pulmonology.ru/pulm/article/view/4875">https://journal.pulmonology.ru/pulm/article/view/4875</self-uri><abstract><p>Муковисцидоз (МВ) — наследственное мультисистемное заболевание, характеризуемое прогрессирующим поражением дыхательной и пищеварительной систем. В Республике Казахстан данные о взрослых пациентах с МВ ограничены, а в отсутствие национального регистра системная оценка клинико-функциональных характеристик этой когорты затруднена.</p><p>Целью исследования являлось пред­ставление генотипических и фенотипических особенностей взрослых пациентов с МВ в Казахстане.</p><sec><title>Материалы и методы</title><p>Материалы и методы. Проанализированы данные взрослых (18 лет и старше) пациентов (n = 29) с подтвержденным диагнозом МВ из различных регионов Казахстана за 2024 г. Оценивались клинические, антропометрические, функциональные, лабораторные, микробиологические и моле­кулярно-генетические параметры в соответствии с протоколами Европейского регистра больных муковисцидозом (European Cystic Fibrosis Society Patient Registry — ECFSPR).</p></sec><sec><title>Результаты</title><p>Результаты. Средний возраст пациентов составил 23,3 года, медиана возраста установления диагноза — 9 лет. Индекс массы тела был ниже целевых значений (19,17 кг / м2). Экзокринная панкреатическая недостаточность выяв­лена у 80 % пациентов (фекальная панкреатическая эластаза-1 &lt; 200 мкг / г), преимущественно у лиц с «тяжелыми» генотипами CFTR. Мутация F508del выявлена в 45 % аллелей. У 72,4 % пациентов определены «тяжелые» генотипы, ассоциированные с более ранней диагностикой, низкими показателями панкреатической функции и высокими уровнями хлоридов пота. Среднее значение объема фор­сированного выдоха за 1-ю секунду составило 60,7 %долж., при этом у 35,8 % пациентов отмечалась тяжелая или очень тяжелая бронхи­альная обструкция. Хроническая инфекция Pseudomonas aeruginosa выявлена у 69 % пациентов. Начало терапии CFTR-модуляторами у большинства больных сопровождалось снижением частоты обострений и потребности во внутривенной антибактериальной терапии.</p></sec><sec><title>Заключение</title><p>Заключение. Взрослые пациенты с МВ в Казахстане характеризуются поздней диагностикой, снижением нутритивного статуса и респи­раторной функции, а также высокой частотой обострений. Интеграция данных в ECFSPR является ключевым шагом к развитию сис­темной помощи и оптимизации терапии МВ в Казахстане.</p></sec></abstract><trans-abstract xml:lang="en"><p>Cystic fibrosis (CF) is a hereditary multisystem disorder characterized by progressive damage to the respiratory and gastrointestinal systems. Data on adult patients with CF are limited in the Republic of Kazakhstan (RK), and the lack of a national registry makes it difficult to evaluate the clinical and functional characteristics of this population.</p><p>The aim was to present the genotypic and phenotypic characteristics of adult patients with CF in the RK.</p><sec><title>Methods</title><p>Methods. Data from 29 adult patients (18 years and older) with a confirmed diagnosis of CF from various regions of the RK for 2024 were analyzed. Clinical, anthropometric, functional, laboratory, microbiological, and molecular genetic parameters were assessed according to European Cystic Fibrosis Society Patient Registry (ECFSPR) protocols.</p></sec><sec><title>Results</title><p>Results. The mean age of patients was 23.3 years, and the median age at diagnosis was 9 years. BMI was below the target values (19.17 kg/m2). Exocrine pancreatic insufficiency was detected in 80% of patients (fecal elastase &lt; 200 pg/g), predominantly in those with “severe” CFTR genotypes. The F508del mutation was detected in 45% of alleles. “Severe” genotypes, associated with earlier diagnosis, low pancreatic function, and high sweat chloride levels, were identified in 72.4% of patients. The mean FEV1 value was 60.7% predicted, with 35.8% of patients experiencing severe or very severe airflow obstruction. Chronic Pseudomonas aeruginosa infection was detected in 69% of patients. Initiation of CFTR modulator therapy was associated with a reduction in the exacerbation frequency and the need for intravenous antibiotic therapy in most patients.</p></sec><sec><title>Conclusion</title><p>Conclusion. Adult patients with CF in Kazakhstan are characterized by late diagnosis, decreased nutritional status and respiratory function, and a high rate of exacerbations. Data integration into the ECFSPR is a key step toward developing systemic care and optimizing CF therapy in the country.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>муковисцидоз</kwd><kwd>CFTR</kwd><kwd>генотип</kwd><kwd>фенотип</kwd><kwd>модуляторы</kwd><kwd>Европейский регистр больных муковисцидозом (ECFSPR)</kwd><kwd>Казахстан</kwd></kwd-group><kwd-group xml:lang="en"><kwd>cystic fibrosis</kwd><kwd>CFTR</kwd><kwd>genotype</kwd><kwd>phenotype</kwd><kwd>modulators</kwd><kwd>European Cystic Fibrosis Society Patient Registry (ECFSPR)</kwd><kwd>Kazakhstan</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">European Cystic Fibrosis Society (ECFS). European Cystic Fibrosis Society Patient Registry (ECFSPR). Available at: https://www.ecfs.eu/ecfspr</mixed-citation><mixed-citation xml:lang="en">European Cystic Fibrosis Society (ECFS). European Cystic Fibrosis Society Patient Registry (ECFSPR). Available at: https://www.ecfs.eu/ecfspr</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Mukatova I., Amelina E., Kim S., Serikova A.S. P066 The first experience of triple targeted therapy in adult patients with cystic fibrosis in Kazakhstan. J. Cyst. Fibros. 2025; 24 (Suppl. 1): S86. DOI: 10.1016/j.jcf.2025.03.084.</mixed-citation><mixed-citation xml:lang="en">Mukatova I., Amelina E., Kim S., Serikova A.S. P066 The first experience of triple targeted therapy in adult patients with cystic fibrosis in Kazakhstan. J. Cyst. Fibros. 2025; 24 (Suppl. 1): S86. DOI: 10.1016/j.jcf.2025.03.084.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Kim S., Mukatova I., Amelina E., Serikova A.S. P095 First results of dual targeted therapy in adult patients with cystic fibrosis in Kazakhstan. J. Cyst. Fibros. 2025; 24 (Suppl. 1): S96. DOI: 10.1016/j.jcf.2025.03.113.</mixed-citation><mixed-citation xml:lang="en">Kim S., Mukatova I., Amelina E., Serikova A.S. P095 First results of dual targeted therapy in adult patients with cystic fibrosis in Kazakhstan. J. Cyst. Fibros. 2025; 24 (Suppl. 1): S96. DOI: 10.1016/j.jcf.2025.03.113.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mukatova I., Amelina E., Kim S., Syzdykova A. P396 Characteristics of adults with cystic fibrosis in Kazakhstan. J. Cyst. Fibros. 2025. 24 (Suppl. 1): S194–S195. DOI: 10.1016/j.jcf.2025.03.1280.</mixed-citation><mixed-citation xml:lang="en">Mukatova I., Amelina E., Kim S., Syzdykova A. P396 Characteristics of adults with cystic fibrosis in Kazakhstan. J. Cyst. Fibros. 2025. 24 (Suppl. 1): S194–S195. DOI: 10.1016/j.jcf.2025.03.1280.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Marshalkina T.V., Zhanuzakova N.T., Mukatova I.Y. et al. The first results of targeted therapy in children with cystic fibrosis in Kazakhstan. Nauka i zdravookhranenie. 2024; 26 (4): 7–14. Available at: https://newjournal.ssmu.kz/index.php/journalssmu/article/view/173/481</mixed-citation><mixed-citation xml:lang="en">Marshalkina T.V., Zhanuzakova N.T., Mukatova I.Y. et al. The first results of targeted therapy in children with cystic fibrosis in Kazakhstan. Nauka i Zdravookhranenie. 2024; 26 (4): 7–14. Available at: https://newjournal.ssmu.kz/index.php/journalssmu/article/view/173/481</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Amelina E., Mukatova i., Kim S., Ramankul A. P009 CFTR gene variants in the group of adult cystic fibrosis patients in Kazakhstan. J. Cyst. Fibrosis. 2025; 24 (Suppl. 1): S69. DOI: 10.1016/j.jcf.2025.03.028.</mixed-citation><mixed-citation xml:lang="en">Amelina E., Mukatova i., Kim S., Ramankul A. P009 CFTR gene variants in the group of adult cystic fibrosis patients in Kazakhstan. J. Cyst. Fibrosis. 2025; 24 (Suppl. 1): S69. DOI: 10.1016/j.jcf.2025.03.028.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Castellani C., Duff A.J.A., Bell S.C. et al ECFS best practice guidelines: the 2018 revision. J. Cyst. Fibros. 2018; 17 (2): 153–117. DOI: 10.1016/j.jcf.2018.02.006.</mixed-citation><mixed-citation xml:lang="en">Castellani C., Duff A.J.A., Bell S.C. et al ECFS best practice guidelines: the 2018 revision. J. Cyst. Fibros. 2018; 17 (2): 153–117. DOI: 10.1016/j.jcf.2018.02.006.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Бюро национальной статистики Агентства по стратегическому планированию и реформам Республики Казахстан. Административно-территориальные единицы Республики Казахстан. 2025. Доступно на: https://stat.gov.kz/upload/iblock/44e/hro69xa2hwk6b3cq1o6bqakgsj9vik04/%D0%92-18-14-%D0%93(%D1%80%D1%83%D1%81).pdf</mixed-citation><mixed-citation xml:lang="en">Bureau of National Statistics of the Agency for Strategic Planning and Reforms of the Republic of Kazakhstan. [Administrative-territorial units of the Republic of Kazakhstan. 2025]. Available at: https://stat.gov.kz/upload/iblock/44e/hro69xa2hwk6b3cq1o6bqakgsj9vik04/%D0%92-18-14-%D0%93(%D1%80%D1%83%D1%81).pdf (in Russian).</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Duguépéroux I., De Braekeleer M. The CFTR 3849+10kbC→T and 2789+5G→A alleles are associated with a mild CF phenotype. Eur. Respir. J. 2005; 25 (3): 468–473. DOI: 10.1183/09031936.05.10100004.</mixed-citation><mixed-citation xml:lang="en">Duguépéroux I., De Braekeleer M. The CFTR 3849+10kbC→T and 2789+5G→A alleles are associated with a mild CF phenotype. Eur. Respir. J. 2005; 25 (3): 468–473. DOI: 10.1183/09031936.05.10100004.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Wilschanski M., Munck A., Carrion E. et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clin. Nutr. 2024; 43 (2): 413–445. DOI: 10.1016/j.clnu.2023.12.017.</mixed-citation><mixed-citation xml:lang="en">Wilschanski M., Munck A., Carrion E. et al. ESPEN-ESPGHAN-ECFS guideline on nutrition care for cystic fibrosis. Clin. Nutr. 2024; 43 (2): 413–445. DOI: 10.1016/j.clnu.2023.12.017.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Zolin A., Adamoli A., Bakkeheim E. et al. ECFSPR annual report 2022. 2024. Available at: https://www.ecfs.eu/sites/default/files/Annual%20Report_2022_ECFSPR_20240603.pdf</mixed-citation><mixed-citation xml:lang="en">Zolin A., Adamoli A., Bakkeheim E. et al. ECFSPR annual report 2022. 2024. Available at: https://www.ecfs.eu/sites/default/files/Annual%20Report_2022_ECFSPR_20240603.pdf</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Middleton P.G., Mall M.A., Dřevěný J. et al. Elexacaftor–Tezacaftor–Ivacaftor for cystic fibrosis with a Phe508del allele. N. Engl. J. Med. 2019; 381 (19): 1809–1819. DOI: 10.1056/NEJMoa1908639.</mixed-citation><mixed-citation xml:lang="en">Middleton P.G., Mall M.A., Dřevěný J. et al. Elexacaftor–Tezacaftor–Ivacaftor for cystic fibrosis with a Phe508del allele. N. Engl. J. Med. 2019; 381 (19): 1809–1819. DOI: 10.1056/NEJMoa1908639.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Cipolli M., Thorat T., Pafundi P.C. et al. Real-world impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in Italy: a retrospective study from a Cystic Fibrosis Center. Pulm. Ther. 2025. DOI: 10.1007/s41030-025-00334-x.</mixed-citation><mixed-citation xml:lang="en">Cipolli M., Thorat T., Pafundi P.C. et al. Real-world impact of elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) in Italy: a retrospective study from a Cystic Fibrosis Center. Pulm. Ther. 2025. DOI: 10.1007/s41030-025-00334-x.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
